PerkinElmer has signed a definitive agreement to acquire Caliper Life Sciences of Hopkinton, Mass., for approximately $600 million.
Waltham, Mass.-based PerkinElmer said in a release that the acquisition received the unanimous support of the boards of directors of both companies. It is expected to close in the fourth quarter this year.
The transaction is subject to customary closing conditions, including approval of Caliper Life Sciences stockholders, and the expiration or termination of a mandated waiting period.
Caliper Life Sciences develops products and services for the pharmaceutical and biotechnology research community. Its CEO, Kevin Hrusovsky, is anticipated to join the PerkinElmer senior leadership team following the close of the transaction, according to the release.